Mindray Medical Investment Quality Review (300760.SZ)

Data timestamp: 2026-08-03 22:13 UTC
Quality score: 83/100
Valuation position: current price/base FV 1.67
Final signal: WATCHLIST

Core Conclusion

Mindray Medical is a strong company but an expensive stock in this framework. Current price of CNY156.89 is 1.67x base FV of CNY94.02 and 2.17x conservative FV of CNY72.28. The signal stays watchlist because quality is high, but valuation blocks action.

Business Breakdown

Five-year revenue CAGR is 1.6%, with latest-year revenue of CNY33.28bn. The medical-device franchise has global potential and attractive returns, but procurement policy, hospital capex cycles, and slower recent growth constrain fair value.

Business Quality

The 83/100 score reflects strong returns, cash conversion, and net cash. Latest-year FCF was CNY8.11bn. Five-year average ROE was 21.6% and average ROIC was 18.9%, making business quality the positive side of the memo.

Financial Audit

Fiscal 2025 revenue was CNY33.28bn, net profit CNY8.14bn, operating cash flow CNY10.14bn, capex CNY2.04bn, and FCF CNY8.11bn. Five-year FCF/net income was 0.91 and OCF/net income was 1.12. Latest net cash was CNY17.34bn.

Valuation

The conservative case uses CNY8.95bn normalized FCF, 0.6% growth, and 8.0x, giving CNY72.28 per share. The base case uses 1.6% growth and 10.9x, giving CNY94.02. The optimistic case uses 3.1% growth and 15.0x, giving CNY124.26. Current price is above all cases.

Buy And Tracking Discipline

The action is watch. A buy requires price/base FV below 0.70, quality at least 75, no deterioration in FCF or ROIC, and evidence that international expansion and product mix can offset policy risk.

Risk Review

Risks include procurement price pressure, hospital capex delays, overseas competition, R&D execution, margin compression, and capital allocation. Sustained FCF/net income below 0.60 or net cash erosion would reduce FV.

Data Sources

The memo relies on public market and financial data, company filings or investor-relations materials, ChinaBond yield data, and public FX data where applicable. This is research only, not personalized investment advice.